Tvardi Therapeutics, Inc. Common Stock (TVRD)

• Market cap: $318M
• 1 day: -4.29%
• 5 days: 8.9%
• 1 month: 43.56%
• 3 months: 29.76%
• 6 months: 121%
• Year to date: 110.7%
• 1 year: 248.2%
• 5 years: -93.93%
• 10 years: -95.36%
• Sector: Healthcare
• Industry: Biotechnology

About: Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,298% more capital invested

Capital invested by funds: $3.21M [Q1] → $44.9M (+$41.7M) [Q2]

733% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 3

129% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 7

67% more funds holding

Funds holding: 33 [Q1] → 55 (+22) [Q2]

16.16% more ownership

Funds ownership: 4.62% [Q1] → 20.78% (+16.16%) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $52
• Avg. target: $57
• High target: $62

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Raymond James Ryan Deschner	$62	Outperform Initiated	14 Jul 2025
Cantor Fitzgerald Steve Seedhouse	$52	Overweight Initiated	11 Jul 2025